ProShare Advisors LLC Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ProShare Advisors LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 113,211 shares of the biopharmaceutical company’s stock after selling 11,992 shares during the quarter. ProShare Advisors LLC owned about 0.10% of Regeneron Pharmaceuticals worth $118,988,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Sachetta LLC increased its holdings in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $26,000. West Paces Advisors Inc. increased its stake in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares in the last quarter. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $28,000. Finally, Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $1,282.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 17th. JPMorgan Chase & Co. raised their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Wells Fargo & Company upped their price target on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, Argus lifted their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,111.30.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 756 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,467,684. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. The disclosure for this sale can be found here. Insiders have sold a total of 10,026 shares of company stock valued at $11,498,705 over the last ninety days. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.4 %

Shares of REGN opened at $1,145.03 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $769.19 and a twelve month high of $1,211.20. The firm has a market capitalization of $126.17 billion, a P/E ratio of 33.83, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The stock’s fifty day simple moving average is $1,131.75 and its 200 day simple moving average is $1,032.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period last year, the business posted $8.79 EPS. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.